Klow
KLOW blend · GHK-Cu + BPC-157 + TB-500 + KPV · Glow + KPV · healing+anti-inflammatory blend
ANECDOTAL · FOUR-COMPONENT REGENERATIVE BLEND (GLOW + KPV ANTI-INFLAMMATORY)
Mechanism of action
Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm.
Researched effects
Inflammatory tissue / mucosal repair; injury and post-surgical recovery; skin regeneration; gut-barrier support when inflammation is part of the picture; broader repair spectrum than Glow alone (adds the KPV anti-inflammatory arm)
Dosing reported in literature
Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose
Known concerns
No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders
No references match — clear filters.
Curated sources on file
5- 1.
- 2.
- 3.
- 4.
-
5.
Note: Klow is a vendor-marketed multi-peptide blend with no published human trials of the combination; component ratios vary by compounder. Cited papers describe each component separately.